阿托伐他汀/培哚普利/氨氯地平
| 组成 | |
|---|---|
| 阿托伐他汀 | 他汀類藥物 |
| 培哚普利 | 血管紧张素转换酶抑制剂 |
| 氨氯地平 | 鈣通道阻滯劑 |
| 臨床資料 | |
| 商品名 | Valongix; Stapressial; Lipertance; Triveram; others[1] |
| 给药途径 | 口服 |
阿托伐他汀/培哚普利/氨氯地平是一种口服複方藥，用于治疗高血壓、高膽固醇血症或心血管疾病[2] [3]。它可以降低近50%的心脏病风险[3]。複方藥合併成一粒药丸的好处是服用意用增加[3]。
副作用是就是个各成分的副作用，但一般來說很少見[3]。培哚普利可以减轻氨氯地平引起的腿部肿胀[3]。它是阿托伐他汀（一种他汀類藥物） 、培哚普利（一种血管紧张素转换酶抑制剂）和氨氯地平（一种鈣通道阻滯劑）的组合[3]。
自 2021 年起，此组合已在许多欧洲国家取得醫療使用許可[1]。名列世界卫生组织基本药物标准清单[4]。它是一种复方制剂[3]。一般來說，组合药物的价格會比各別单一药物藥價的總合便宜，但可能因国家而异[5] [6]。
参考文獻
[编辑]- ^ 1.0 1.1 List of nationally authorised medicinal products (PDF). EMA. [18 September 2023]. （原始内容存档 (PDF)于3 March 2022）.
- ^ 2.0 2.1 European Medicines Agency decision P/0300/2013 (PDF). EMA. [18 September 2023]. （原始内容存档 (PDF)于19 September 2023）.
- ^ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Bertrand, ME; Vlachopoulos, C; Mourad, JJ. Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine.. American journal of cardiovascular drugs : drugs, devices, and other interventions. August 2016, 16 (4): 241–253. PMID 27256435. doi:10.1007/s40256-016-0175-2.
- ^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.
- ^ Stafylas, P.; Karaiskou, M.; Zouka, M. PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTING. Value in Health. October 2018, 21: S99–S100 [24 September 2023]. doi:10.1016/j.jval.2018.09.590. （原始内容存档于19 October 2023）.
- ^ An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention of atherosclerotic cardiovascular diseases in adults (PDF). WHO. [24 September 2023]. （原始内容存档 (PDF)于19 October 2023）.